Respiratory Drugs Market is forecast to rise from a value of $28.1 Respiratory Drugs Market 2022 | Page 5

2.5.3 Idiopathic Pulmonary Fibrosis 23
2.5.4 Cystic Fibrosis 24
2.6 Disease Severity and Prognosis 24
2.6.1 Asthma 24
2.6.2 Chronic Obstructive Pulmonary Fibrosis 27
2.6.3 Idiopathic Pulmonary Fibrosis 29
2.6.4 Cystic Fibrosis 30
2.7 Treatment 32
2.7.1 Asthma 32
2.7.2 Chronic Obstructive Pulmonary Fibrosis 33
2.7.3 Idiopathic Pulmonary Fibrosis 33
2.7.4 Cystic Fibrosis 34
3 Key Marketed Products 36
3.1 Overview 36
3.2 Advair - GSK 37
3.3 Spiriva - Boehringer Ingelheim, Pfizer 39
3.4 Symbicort - AstraZeneca/Astellas 41
3.5 Singulair (montelukast) - Merck & Co. 43
3.6 Flixotide/Flovent - GSK 45
3.7 Ventolin - GSK 47
3.8 Kalydeco - Vertex 48
3.9 Pulmozyme - Roche 50
3.10 Esbriet - Roche 51
3.11 TOBI - Novartis 53
3.12 Conclusion 54
Follow Us: